Harnessing the natural healing power of macrophages to treat inflammatory diseases.

Enlivex’s proprietary off-the-shelf cell therapy platform Allocetra™ with its novel therapeutic mechanism has the potential to redefine the way inflammatory diseases are treated.

INVESTOR OVERVIEW

Allocetra™ offers off-the-shelf and easy to use, flexible administration options, including systemic intravenous infusion or targeted local injections.

Over 150 patients have been safely treated with Allocetra™ in various clinical trials, with no reported drug related serious adverse events.

LEARN MORE
ABOUT ALLOCETRA™

Our programs

Enlivex is evaluating Allocetra™ for the treatment of multiple indications including acute inflammatory diseases such as sepsis and chronic inflammatory diseases like osteoarthritis.

SEE OUR PIPELINE FOR
CURRENT CLINICAL TRIALS

If you would like to learn more about Enlivex, Allocetra™ or are interested in participating in one of our clinical trials, please contact us.